Extracorporeal shock wave therapy (ESWT) is an efficient treatment for chronic prostatitis/chronic pelvic pain syndrome (CPPS) patients, according to a study published in the Prostate Cancer and Prostatic Diseases.
Extracorporeal Shockwave Therapy (ESWT) otherwise referred to as shockwave therapy, was first introduced into clinical practice in 1982 for management of urologic conditions. The success of this technology for the treatment of urinary stones quickly made it a first-line, noninvasive, and effective method.
A group of researchers from Egypt conducted a study to report the one-year results of extracorporeal shock wave therapy (ESWT) on chronic prostatitis/chronic pelvic pain syndrome (CPPS) patients and the possible clinical characteristics that may affect its efficacy.
A prospective randomized clinical study between January 2017 and January 2021 on 155 adult patients with chronic pelvic pain syndrome. All patients were initially evaluated with a thorough history and physical examination. Baseline symptoms evaluation of each participant was assessed using NIH-CPSI score, IPSS, VAS, and IIEF-5 score. Patients were randomized into two groups: a verum treatment group and a placebo treatment group. Patients of verum group in the lithotomy position received a perineally applied Extracorporeal shock wave therapy (ESWT) treatment once a week for four weeks with 3000 impulses each. Patients of the placebo group received the same therapy head of the same device with a layer of air-filled microspheres to absorb the shock waves. The previously mentioned validated scores were reassessed on regular follow-up visits at one, three, six, and 12 months after the completion of Extracorporeal shock wave therapy (ESWT).
The results of the study are as follows:
A statistically significant improvement was noticed in the mean values of NIH-CPSI, IPSS, VAS, and IIEF-5 of the patients of verum group over the follow-up period with also statistically significant difference between both groups.
At the first visit of follow-up after ESWT, 63 (82.8%) patients had ≥6 points decrease in the NIH-CPSI total score, while 13 (17.2%) patients did not. Univariate and multivariate analyses of the clinical characteristics between the responders and non-responders showed that those patients with history of psychological disorders or had higher initial NIH-CPSI scores had a significantly lower response rate to ESWT
ROC curve of NIH-CPSI score showed that a score of 32 was the cut-off point above which the response to Extracorporeal shock wave therapy (ESWT) decreased.
Thus, the researchers concluded that Extracorporeal shock wave therapy (ESWT) is an effective treatment option for chronic prostatitis/chronic pelvic pain syndrome (CPPS). Its efficacy remained throughout long-term follow up. High initial NIH-CPSI score and history of psychological problems are significant predictors for it.
Reference:
Outcomes and clinical predictors of extracorporeal shock wave therapy in the treatment of chronic prostatitis/chronic pelvic pain syndrome: a prospective randomized double-blind placebo-controlled clinical trial by Ahmed M. Sakr et al. published in the Prostate Cancer and Prostatic Diseases.
https://doi.org/10.1038/s41391-021-00464-8